CryoLife Aktie News

Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion, Inc. (AORT) were among the top contributors to performance. SPS Commerce, Inc. (SPSC), Palomar Holdings, Inc. (PLMR), and Vertex, Inc. (VRTX) were among the top detractors from performance.

Artivion, Inc. ( AORT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Pat MacKin Lance Berry - EVP, COO, CFO & Treasurer Conference Call Participants Lynn Lewis - Gilmartin Group LLC John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Resear...

Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025 Adjusted...

ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent Graft System ("Arcevo LSA") in the treatment of acute and chronic arch pathologies. The trial is desig...

ATLANTA , Oct. 29, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025, at the Lotte New York Palace Hotel. The Company's fireside chat is scheduled to begin at 8:00 a.m.

ATLANTA , Oct. 23, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.

30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data from the AMDS PROTECT Trial Validate Statistically Significant Positive Outcomes Demonstrated by the PERSEVERE and DARTS trials ATLANTA , Oct. 13, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a l...

Artivion, Inc. (NYSE:AORT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 2:35 PM EDT Company Participants James Mackin - Chairman, President & CEO Lance Berry - COO, CFO & Treasurer Presentation Unknown Analyst Perfect. Great. Thanks, everyone, for being with us.